Page last updated: 2024-12-08
cryptoporic acid e
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cryptoporic acid E: from fungus Cryptoporus volvatus; inhibitor of superoxide anion radical release; inhibits tumor promotion of okadaic acid; RN given from Chem Abstr Index Guide 1991; RN given refers to (1S-(1alpha(1S*,2R*),4alpha, beta,5beta(2R*,3S*(1R*,4aS*,5S*,8aR))8aalpha))-isomer; RN for cpd without isomeric designation not avail 7/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 147476 |
| CHEMBL ID | 4868875 |
| SCHEMBL ID | 20576741 |
| MeSH ID | M0188947 |
Synonyms (9)
| Synonym |
|---|
| cryptoporic acid e |
| (3s,4r)-4-[[(1s,4ar,5r,8as)-5-[[(2s,3r)-3-[[(1s,4ar,5r,8as)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]methoxy]-2-(carboxymethyl)-4-methoxy-4-oxobutanoyl]oxymethyl]-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexa |
| 120001-10-7 |
| 1,2,3-propanetricarboxylic acid, 1-((5-((2-(carboxymethyl)-3-((decahydro-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)methoxy)-4-methoxy-1,4-dioxobutoxy)methyl)decahydro-5,8a-dimethyl-2-methylene-1-naphthalenyl)methoxy)-, 1,2-dimethyl ester, |
| ccris 6990 |
| 4r12b7j65a , |
| unii-4r12b7j65a |
| SCHEMBL20576741 |
| CHEMBL4868875 |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with cryptoporic acid E using two different doses per application, 1 (1.2 mumol) and 5 mg (5.9 mumol), reduced the percentage of tumor-bearing mice from 73.3 to 53.3% and 20.0%, and the average number of tumors per mouse from 4.2 to 2.3 and 0.5 respectively in week 20 of tumor promotion." | ( Differential effects of cryptoporic acids D and E, inhibitors of superoxide anion radical release, on tumor promotion of okadaic acid in mouse skin. Asakawa, Y; Fujiki, H; Furuya-Suguri, H; Hashimoto, T; Matsunaga, S; Nishiwaki, S; Suganuma, M; Yoshizawa, S, 1991) | 0.62 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1753117 | Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay | 2021 | Journal of natural products, 02-26, Volume: 84, Issue:2 | Species Prioritization Based on Spectral Dissimilarity: A Case Study of Polyporoid Fungal Species. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||